Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

[Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].

Schmutz JL, Trechot P.

Ann Dermatol Venereol. 2012 Oct;139(10):695-6. doi: 10.1016/j.annder.2012.05.019. Epub 2012 Jun 27. French. No abstract available.

PMID:
23122389
2.

Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.

Erten S.

Rheumatol Int. 2011 Nov;31(11):1537-8. doi: 10.1007/s00296-010-1661-5. Epub 2010 Dec 1. No abstract available.

PMID:
21120492
3.

Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.

Imafuku S, Tatsukawa R, Ito K, Nakayama J.

J Dermatol. 2012 Dec;39(12):1070. doi: 10.1111/j.1346-8138.2012.01602.x. Epub 2012 Jun 14. No abstract available.

PMID:
22698067
4.

TNFalpha therapy in psoriatic arthritis and psoriasis.

Mease P.

Ann Rheum Dis. 2004 Jul;63(7):755-8. No abstract available.

5.

Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis.

Imafuku S, Ito K, Nakayama J.

Br J Dermatol. 2012 Mar;166(3):675-8. doi: 10.1111/j.1365-2133.2011.10607.x. Epub 2011 Nov 8. No abstract available.

PMID:
21910704
6.

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.

Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.

Immunopharmacol Immunotoxicol. 2012 Aug;34(4):548-60. doi: 10.3109/08923973.2011.653646. Epub 2012 Feb 2. Review.

PMID:
22296031
7.

Treatment of spondyloarthritides with anti-TNFalpha biologic agents.

Braun J.

Reumatismo. 2006 Jan-Mar;58 Spec No.1:71-2. No abstract available.

8.

Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.

Garcovich S, Burlando M, Rongioletti F, Garcovich A, Parodi A, Amerio P.

Acta Derm Venereol. 2010 May;90(3):311-2. doi: 10.2340/00015555-0839. No abstract available.

9.

Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.

Montesu MA, Addis GM, Satta R, Cottoni F.

G Ital Dermatol Venereol. 2011 Aug;146(4):273-81. Review.

PMID:
21785393
10.

Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.

Sadlier M, Lally A, Kirby B.

Br J Dermatol. 2012 Oct;167(4):937-8. doi: 10.1111/j.1365-2133.2012.10947.x. Epub 2012 Jun 11. No abstract available.

PMID:
22428935
11.

Alopecia areata universalis elicited during treatment with adalimumab.

Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N.

Dermatology. 2008;216(4):320-3. doi: 10.1159/000113945. Epub 2008 Jan 29.

PMID:
18230980
12.

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

De Simone C, Amerio P, Amoruso G, Bardazzi F, Campanati A, Conti A, Gisondi P, Gualdi G, Guarneri C, Leoni L, Loconsole F, Mazzotta A, Musumeci ML, Piaserico S, Potenza C, Prestinari F.

Expert Opin Biol Ther. 2013 Dec;13(12):1673-82. doi: 10.1517/14712598.2013.848194. Epub 2013 Oct 10. Review.

PMID:
24107126
13.

Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.

Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW.

Curr Pharm Des. 2014;20(4):513-28. Review.

PMID:
23565632
14.

Ustekinumab for resistant psoriatic arthritis.

Wallis DE, Waldron NM, Korendowych E.

J Rheumatol. 2013 Feb;40(2):207. doi: 10.3899/jrheum.121152. No abstract available.

PMID:
23378500
15.

Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.

Papoutsaki M, Costanzo A, Chimenti MS, Chimenti S.

Expert Opin Biol Ther. 2008 Mar;8(3):363-70. doi: 10.1517/14712598.8.3.363 . Review.

PMID:
18294106
16.

Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.

Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L.

Scand J Rheumatol. 2012;41(6):490-1. doi: 10.3109/03009742.2012.698393. Epub 2012 Sep 18. No abstract available.

PMID:
22985209
17.

Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?

Orr C, Veale DJ.

Ann Rheum Dis. 2014 Jun;73(6):951-3. doi: 10.1136/annrheumdis-2013-204934. No abstract available.

PMID:
24790066
18.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
19.

["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].

Schmutz JL, Trechot P.

Ann Dermatol Venereol. 2013 Feb;140(2):157-8. doi: 10.1016/j.annder.2012.12.010. Epub 2013 Jan 16. French. No abstract available.

PMID:
23395504
20.

Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?

Richette P, Viguier M, Bachelez H, Bardin T.

J Rheumatol. 2007 Feb;34(2):438-9. No abstract available.

PMID:
17304662

Supplemental Content

Support Center